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Frailty in older adults with cancer
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 About onehalf of cancer cases and two-thirds of cancer deaths occur in patients 65 years of age or older. Therefore, un-
derstanding the health status of an older patient is just as important as staging of the cancer.
 Frailty is a complex, multidimensional syndrome of increased vulnerability and loss of adaptive capacity/resistance to 
external stressors, resulting in an increased risk of adverse outcomes. Clinical presentation is non-specific: fatigue, un-
explained weight loss, frequent infections, decline in physical mobility/balance/gait speed. Therefore, the routine format 
of preoperative investigations often does not allow for adequate frailty identification. There are two principal models of 
frailty: the phenotype model and the accumulation of deficits model. There is no consensus on an operational definition 
of frailty. However, it has been demonstrated that frailty, not chronological age, is the most important risk factor for poor 
outcome. Therefore, frailty identification should be obligatory before the beginning of the oncologic treatment.
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Similarly to other European countries, Poland’s population 
is aging. In early 2030s, one-third of Poland’s population will 
be aged 65 or older; in particular, the 80+ group will double. 
There also is a gender imbalance at older ages. Almost 60% of 
older adults aged 70–74 years are female and this proportion 
increases to 76% for those 90–94 years old [1]. Additionally, 
taking the oncological context into consideration, about one-
half of cancer cases and two-thirds of cancer deaths occur in 
patients 65 years of age or older [2]. As the incidence of cancer 
increases with age, the number of elderly patients with cancer 
is expected to rise markedly in the next decade. However, this 
group of patients is very heterogeneous with regard to co-mor-
bidity, physical reserve, cognitive function and social support. 
Studies report that 50% of patients over 70 years experience 
severe chemotherapy-related toxicity [3] and more than half 
have postoperative complications [4]. Therefore, identification 
of patients at risk is the key element for optimal and tailored 
treatment, particularly of cancer patients [5]. 
Frailty, by definition, is a complex, multidimensional, trans-
itional state of increased vulnerability and loss of adaptive ca-
pacity/resistance to external stressors, resulting in an increased 
risk of adverse outcomes, both in the short and long term [5–7]. 
These external stressors comprise factors such as hospitaliza-
tion, surgery, illness (even mild one in some frail patients) or 
environmental factors. In turn, adverse outcomes associated 
with frailty include: disability, hospitalization, postoperative 
complications, functional dependence, institutionalization, 
social withdrawal and death. In the context of cancer-specific 
treatment, it increases the risk of chemotherapy intolerance, 
disease recurrence and progression [8]. 
It is important to keep in mind that frailty is a concept, not 
an illness, and it is proposed to be used as a “clinical state varia-
ble”, quantifying the underlying health status of the person [6]. 
In fit older adults, following a minor stressor, we observe 
a minor deterioration in function, followed by the return to 
homeostasis. In contrast, in a frail older patient a similar stres-
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sor causes a significant deterioration and, usually, without the 
return to the baseline homeostasis. This can lead to disability 
and death. Of note is that frailty is a dynamic state; in majority 
of population it will be chronic and progressing, however, in 
some patients it may be reversed to some extent [5].
The incidence of frailty is estimated to be between 10 and 
20% of patients 65 or more of age and 25–50% of patients 85+. 
However, the number depends on the assessed population 
and instruments used for it [9]. 
The etiopathogenesis of the frailty syndrome is complex 
and has not been fully understood. It is believed that a number 
of mechanisms may play a role: genetic factors, oxidative stress, 
mitochondrial dysfunction, chronic diseases that accelerate 
the development of the syndrome, lifestyle and the changes 
associated with the aging process [10]. Therefore, the frailty risk 
factors include: advanced age, polypharmacy, low physical fit-
ness, cognitive disorders, malnutrition (low protein diet, deficits 
of multiple vitamins), poverty and isolation [10].
Frailty syndrome may not be evident to patients, family 
members, and – what is more important – to the untrained 
clinicians. Older people, who are classified as frail, frequently do 
not identify themselves as such [11]. By definition, manifesta-
tions associated within a syndrome occur in combination, and 
no single manifestation is sufficient to identify those with the 
syndrome. Clinical presentation is non-specific: fatigue, une-
xplained weight loss, frequent infections, decline in physical 
mobility, balance and gait impairment, delirium, fluctuating 
disability. Therefore, the routine format of, medical history, 
physical examination, biochemistry and imaging tests often do 
not provide the information needed for optimal identification 
of frailty. This is due that fact that it does not fit into classic 
organ-specific models of disease, there is a gradual decline in 
strength, endurance, and nutrition may not cause patients to 
seek medical attention and it often is attributed to old age [10]. 
Most of the physicians identify frailty with disability and/
or multi-comorbidity. Fried et al. examined the similarities 
and differences between those three factors. While there was 
a 21.5% overlap between the three categories, many more 
people were categorised into just one category or a mix of two 
categories. Only 6% of frail population was disabled (defined 
as being dependent in one or more activities of daily living), 
46% had comorbidity (defined as the presence of 2 or more 
comorbid diseases), but – most importantly – 27% of frail 
population had neither poor function nor comorbidity [12]. 
Frailty is different conceptually from ageing, disability and co-
-morbidity, although it is related to these factors. Its prevalence 
increases with age, however, it occurs independently from 
chronological age [12].
The concept of frailty is still debatable and at present there 
are two principal models of it: the phenotype model described 
by Fried et al. [12] and the cumulative deficit model proposed 
originally by Rockwood [13]. The first model, widely used 
(though it has not been validated in older cancer patients), 
is based on the concept that a clinical syndrome driven by 
age-related biologic changes that drive physical characteri-
stics of frailty and eventually, adverse outcomes. The frailty 
phenotype, introduced by Fried et al., was defined as meeting 
three or more of the following criteria: unintentional weight 
loss, self-reported exhaustion, slow walking speed, weak grip 
strength, and low physical activity level [12]. In turn, the basis 
of the deficit model is the accumulation of medical, functional, 
cognitive and social deficits that can be assessed using Ge-
riatric Assessment and allowing to quantitatively summarize 
vulnerability. The research conducted in our centre showed 
that the model based on the accumulation of deficits had 
the highest predictive power in the preoperative evaluation 
of older patients with cancer. The sum of tools, not individual 
results, was an independent risk factor for 30-day mortality 
and postoperative complications. In turn, the number and 
type of incorporated instruments had a great influence on the 
prevalence of frailty and on adequate surgical risk assessment 
[14–15]. At present, we have good evidence that preoperative 
identification of frailty can forecast areas of vulnerability, tre-
atment outcome (including morbidity and mortality), length 
of hospitalization and need for discharge to a skilled nursing 
facility. This knowledge allows for the tailored approach im-
proving the treatment outcome and avoiding unnecessary 
harm, particularly to frail older patients. 
Conclusions
Frailty is not a disease; it is a concept, unifying the care of older 
patients and directing attention away from organ-specific 
diagnoses towards a more holistic viewpoint of the patient. 
At present, there is no consensus on an operational definition 
of frailty which differs among authors and studies. However, 
there is more than good evidence that overtreatment in the 
frail patient can lead to unacceptable outcomes with high 
mortality or persistent disability. Moreover, in this population 
quality of life, functional decline and toxicity of the treatment 
is often much more important than prolonging of life alone. 
Therefore, identification of frailty should be obligatory before 
the beginning of the oncologic treatment.
This mini-review is the first part of the series, prepared 
by the Oncogeriatric Section of the Polish Society of Surgical 
Oncology, aiming the dissemination of knowledge on diagno-
stic and high-quality treatment of older patient with cancer.
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